{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:13:31Z","timestamp":1792602811614,"version":"4.5.0"},"reference-count":84,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002599"],"award-info":[{"award-number":["82002599"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>The purpose of this meta-analysis was to evaluate the efficacy and safety of celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, in addition to standard anticancer therapy. Randomized controlled trials (RCTs) that evaluated the efficacy and safety of celecoxib-combined cancer therapy were systematically searched in PubMed and Embase databases. The endpoints were overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), objective response rate (ORR), disease control rate (DCR), pathological complete response (pCR), and adverse events (AEs). The results of 30 RCTs containing 9655 patients showed limited benefits in celecoxib-combined cancer therapy. However, celecoxib-combined palliative therapy prolonged PFS in epidermal growth factor receptor (EGFR) wild-type patients (HR = 0.57, 95%CI = 0.35\u20130.94). Moreover, despite a slight increase in thrombocytopenia (RR = 1.35, 95%CI = 1.08\u20131.69), there was no increase in other toxicities. Celecoxib combined with adjuvant therapy indicated a better OS (HR = 0.850, 95%CI = 0.725\u20130.996). Furthermore, celecoxib plus neoadjuvant therapy improved the ORR in standard cancer therapy, especially neoadjuvant therapy (overall: RR = 1.13, 95%CI = 1.03\u20131.23; neoadjuvant therapy: RR = 1.25, 95%CI = 1.09\u20131.44), but not pCR. Our study indicated that adding celecoxib to palliative therapy prolongs the PFS of EGFR wild-type patients, with good safety profiles. Celecoxib combined with adjuvant therapy prolongs OS, and celecoxib plus neoadjuvant therapy improves the ORR. Thus, celecoxib-combined cancer therapy may be a promising therapy strategy.<\/jats:p>","DOI":"10.3390\/curroncol29090482","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T21:28:12Z","timestamp":1661462892000},"page":"6137-6153","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["The Efficacy and Safety of Celecoxib in Addition to Standard Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.3390","volume":"29","author":[{"given":"Shi-Yu","family":"Ye","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 155 N. Nanjing Street, Shenyang 110002, China"},{"name":"Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang 110122, China"},{"name":"Institute of Health Sciences, China Medical University, Shenyang 110122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 155 N. Nanjing Street, Shenyang 110002, China"},{"name":"Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang 110122, China"},{"name":"Institute of Health Sciences, China Medical University, Shenyang 110122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng-Hui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 155 N. Nanjing Street, Shenyang 110002, China"},{"name":"Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang 110122, China"},{"name":"Institute of Health Sciences, China Medical University, Shenyang 110122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Xi","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 155 N. Nanjing Street, Shenyang 110002, China"},{"name":"Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang 110122, China"},{"name":"Institute of Health Sciences, China Medical University, Shenyang 110122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Xu","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 155 N. Nanjing Street, Shenyang 110002, China"},{"name":"Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang 110122, China"},{"name":"Institute of Health Sciences, China Medical University, Shenyang 110122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Wan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 155 N. Nanjing Street, Shenyang 110002, China"},{"name":"Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang 110122, China"},{"name":"Institute of Health Sciences, China Medical University, Shenyang 110122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Hua","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 155 N. Nanjing Street, Shenyang 110002, China"},{"name":"Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang 110122, China"},{"name":"Institute of Health Sciences, China Medical University, Shenyang 110122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 155 N. Nanjing Street, Shenyang 110002, China"},{"name":"Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang 110122, China"},{"name":"Institute of Health Sciences, China Medical University, Shenyang 110122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Hua","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 155 N. Nanjing Street, Shenyang 110002, China"},{"name":"Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang 110122, China"},{"name":"Institute of Health Sciences, China Medical University, Shenyang 110122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 155 N. Nanjing Street, Shenyang 110002, China"},{"name":"Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang 110122, China"},{"name":"Institute of Health Sciences, China Medical University, Shenyang 110122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan-Zhang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 155 N. Nanjing Street, Shenyang 110002, China"},{"name":"Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang 110122, China"},{"name":"Institute of Health Sciences, China Medical University, Shenyang 110122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1002\/cncr.33587","article-title":"The ever-increasing importance of cancer as a leading cause of premature death worldwide","volume":"127","author":"Bray","year":"2021","journal-title":"Cancer"},{"key":"ref_2","first-page":"481","article-title":"Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer","volume":"5","author":"Krysan","year":"2013","journal-title":"Am. J. Transl. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1200\/JCO.2005.09.112","article-title":"Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention","volume":"23","author":"Dannenberg","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1172\/JCI13271","article-title":"Why there are two cyclooxygenase isozymes","volume":"107","author":"Smith","year":"2001","journal-title":"J. Clin. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.1572-0241.2002.05625.x","article-title":"Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer","volume":"97","author":"Zhang","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"ref_7","first-page":"632","article-title":"Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer","volume":"62","author":"Sivula","year":"2002","journal-title":"Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1158\/1940-6207.CAPR-09-0077","article-title":"Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma","volume":"2","author":"Saba","year":"2009","journal-title":"Cancer Prev. Res."},{"key":"ref_9","first-page":"1306","article-title":"Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors","volume":"60","author":"Masferrer","year":"2000","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/01.CIR.102.8.840","article-title":"Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis","volume":"102","author":"Belton","year":"2000","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","article-title":"Risk of cardiovascular events associated with selective COX-2 inhibitors","volume":"286","author":"Mukherjee","year":"2001","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"El-Malah, A.A., Gineinah, M.M., Deb, P.K., Khayyat, A.N., Bansal, M., Venugopala, K.N., and Aljahdali, A.S. (2022). Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing. Pharmaceuticals, 15.","DOI":"10.3390\/ph15070827"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"djw151","DOI":"10.1093\/jnci\/djw151","article-title":"Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial","volume":"108","author":"Thompson","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJMoa061355","article-title":"Celecoxib for the prevention of sporadic colorectal adenomas","volume":"355","author":"Bertagnolli","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/bju.13612","article-title":"Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention: Double-blind randomised study of pre-prostatectomy celecoxib or placebo","volume":"119","author":"Flamiatos","year":"2017","journal-title":"BJU Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1158\/1940-6207.CAPR-21-0524","article-title":"The Importance of Drug Concentration at the Site of Action: Celecoxib and Colon Polyp Prevention as a Case Study","volume":"15","author":"Thompson","year":"2022","journal-title":"Cancer Prev. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/1940-6207.CAPR-11-0078","article-title":"Lung cancer chemoprevention with celecoxib in former smokers","volume":"4","author":"Mao","year":"2011","journal-title":"Cancer Prev. Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Tudor, D.V., Baldea, I., Olteanu, D.E., Fischer-Fodor, E., Piroska, V., Lupu, M., Calinici, T., Decea, R.M., and Filip, G.A. (2021). Celecoxib as a Valuable Adjuvant in Cutaneous Melanoma Treated with Trametinib. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094387"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2174\/1389450119666180803121737","article-title":"Celecoxib in Cancer Therapy and Prevention\u2014Review","volume":"20","author":"Nowaszewska","year":"2019","journal-title":"Curr. Drug Targets"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"11397","DOI":"10.1074\/jbc.275.15.11397","article-title":"The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2","volume":"275","author":"Hsu","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_21","first-page":"31","article-title":"Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity","volume":"16","author":"Lin","year":"2002","journal-title":"Oncology"},{"key":"ref_22","first-page":"9454","article-title":"Effect of celecoxib on protein expression of FAK and Cx43 in DMBA induced rat tongue carcinoma cells","volume":"23","author":"Shan","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Medina, M.V., D\u2019Agostino, A., Ma, Q., Eroles, P., Cavallin, L., Chiozzini, C., Sapochnik, D., Cymeryng, C., Hyjek, E., and Cesarman, E. (2020). KSHV G-protein coupled receptor vGPCR oncogenic signaling upregulation of Cyclooxygenase-2 expression mediates angiogenesis and tumorigenesis in Kaposi\u2019s sarcoma. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1009006"},{"key":"ref_24","first-page":"5793","article-title":"Celecoxib suppresses lipopolysaccharide-stimulated oral squamous cell carcinoma proliferation in vitro and in vivo","volume":"18","author":"Yoshida","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1177\/0963689719890597","article-title":"Cyclooxygenase 2 Promotes Proliferation and Invasion in Ovarian Cancer Cells via the PGE2\/NF-kappaB Pathway","volume":"28","author":"Zhang","year":"2019","journal-title":"Cell Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.2147\/CMAR.S183376","article-title":"Suppressing growth and invasion of human hepatocellular carcinoma cells by celecoxib through inhibition of cyclooxygenase-2","volume":"11","author":"Tai","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/annonc\/mdr400","article-title":"Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: Result of a single-center, prospective randomized phase III trial","volume":"23","author":"Zhang","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000329529","article-title":"Celecoxib, a selective cyclooxygenase-2 inhibitor, attenuates renal injury in a rat model of Cisplatin-induced nephrotoxicity","volume":"57","author":"Suddek","year":"2011","journal-title":"Chemotherapy"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10549-008-0229-5","article-title":"Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: A double-blind phase III GINECO study","volume":"116","author":"Falandry","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.radonc.2009.08.006","article-title":"Double blind randomized phase II study with radiation + 5-fluorouracil \u00b1 celecoxib for resectable rectal cancer","volume":"93","author":"Debucquoy","year":"2009","journal-title":"Radiother. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.ejca.2011.03.035","article-title":"Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group","volume":"47","author":"Koch","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/jnci\/djy017","article-title":"Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27","volume":"110","author":"Higgins","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/annonc\/mdl952","article-title":"FOLFIRI with or without celecoxib in advanced colorectal cancer: A randomized phase II study of the Gruppo Oncologico dell\u2019Italia Meridionale (GOIM)","volume":"17","author":"Maiello","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control. Clin. Trials"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/JCO.2016.69.0677","article-title":"Adding Celecoxib With or Without Zoledronic Acid for Hormone-Na\u00efve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial","volume":"35","author":"Mason","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.eururo.2018.09.020","article-title":"BOXIT\u2014A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK\/07\/004)","volume":"75","author":"Kelly","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jsbmb.2008.04.004","article-title":"Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer","volume":"111","author":"Chow","year":"2008","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1200\/JCO.18.00636","article-title":"Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial","volume":"37","author":"Hamy","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_45","first-page":"419","article-title":"Combined neoadjuvant chemotherapy and celecoxib in locally advanced breast cancer","volume":"11","author":"Ahmadloo","year":"2009","journal-title":"Iran. Red Crescent Med. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e16234","DOI":"10.1097\/MD.0000000000016234","article-title":"A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study","volume":"98","author":"Guo","year":"2019","journal-title":"Medicine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1001\/jama.2021.2454","article-title":"Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival among Patients with Stage III Colon Cancer: The CALGB\/SWOG 80702 (Alliance) Randomized Clinical Trial","volume":"325","author":"Meyerhardt","year":"2021","journal-title":"JAMA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e1918070","DOI":"10.1001\/jamanetworkopen.2019.18070","article-title":"Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial","volume":"2","author":"Bi","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"442","DOI":"10.4103\/0973-1482.92013","article-title":"Efficacy and safety of concurrent chemoradiation with weekly cisplatin \u00b1 low-dose celecoxib in locally advanced undifferentiated nasopharyngeal carcinoma: A phase II-III clinical trial","volume":"7","author":"Mohammadianpanah","year":"2011","journal-title":"J. Cancer Res. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e103653","DOI":"10.5812\/ijcm.103653","article-title":"The efficacy of celecoxib during chemoradiation in locally advanced head and neck carcinoma; a phase 2 randomized placebo control clinical trial","volume":"14","author":"Aghili","year":"2021","journal-title":"Int. J. Cancer Manag."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1200\/JCO.2007.13.8081","article-title":"Eicosanoid modulation in advanced lung cancer: Cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy\u2014Cancer and leukemia group B trial 30203","volume":"26","author":"Edelman","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdm544","article-title":"Irinotecan combined with infusional 5-fluorouracil\/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015","volume":"19","author":"Hartmann","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"PD2\u201302","DOI":"10.1158\/1538-7445.SABCS15-PD2-02","article-title":"NEO-EXCEL phase III neoadjuvant trial of pre-operative exemestane or letrozole +\/\u2212 celecoxib in the treatment of ER positive postmenopausal early breast cancer","volume":"76","author":"Rea","year":"2016","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): A single-centre, parallel-group, non-comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"9603","DOI":"10.1200\/jco.2004.22.90140.9603","article-title":"Neoadjuvant use of 5-fluorouracil, epirubicin and cyclophosphamide with and without celecoxib for locally advanced breast cancer: A phase II study correlating response to celecoxib with high levels of COX-2 gene expression in the tumor","volume":"22","author":"Chow","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1177\/147323001103900609","article-title":"Observation of curative efficacy and prognosis following combination chemotherapy with celecoxib in the treatment of advanced colorectal cancer","volume":"39","author":"Jin","year":"2011","journal-title":"J. Int. Med. Res."},{"key":"ref_57","first-page":"S702","article-title":"P2-327: First-line chemotherapy of vinorelbine\/cisplatin (NP) combined with cyclooxygenase-2 inhibitor celecoxib in advanced non-small-cell lung cancer (NSCLC)","volume":"2","author":"Zhou","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2016.71.3743","article-title":"Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)","volume":"35","author":"Edelman","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1002\/cncr.29480","article-title":"Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer","volume":"121","author":"Reckamp","year":"2015","journal-title":"Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1093\/annonc\/mds107","article-title":"A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: The DoCaCel study","volume":"23","author":"Reyners","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1200\/JCO.2006.07.4773","article-title":"Randomized phase II trial of docetaxel\/irinotecan and gemcitabine\/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer","volume":"24","author":"Lilenbaum","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"100155","DOI":"10.1016\/j.ctarc.2019.100155","article-title":"Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer","volume":"21","author":"Gupta","year":"2019","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1200\/JCO.2011.35.5214","article-title":"Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: The NVALT-4 study","volume":"29","author":"Groen","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_64","first-page":"1","article-title":"Role of COX-2 inhibitors as maintenance therapy in non-metastatic triple negative breast cancer Egyptian patients, single institution study","volume":"1","author":"Gharib","year":"2020","journal-title":"Oncol. Radiother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1200\/JCO.2007.13.3744","article-title":"Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib","volume":"26","author":"Dirix","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"CT238","DOI":"10.1158\/1538-7445.AM2014-CT238","article-title":"Phase III randomized, placebo controlled trial of COX-2 inhibition in addition to standard chemotherapy for advanced non-small cell lung cancer (NSCLC):CALGB 30801 (Alliance)","volume":"74","author":"Edelman","year":"2014","journal-title":"Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/0284186X.2017.1400685","article-title":"COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer","volume":"57","author":"Gulyas","year":"2018","journal-title":"Acta Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-010-0939-3","article-title":"A multicenter randomized phase II study of sequential epirubicin\/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients","volume":"122","author":"Pierga","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_70","first-page":"2699","article-title":"Approaches to prevention of epithelial cancer during the preneoplastic period","volume":"36","author":"Sporn","year":"1976","journal-title":"Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc844","article-title":"Chemoprevention: An essential approach to controlling cancer","volume":"2","author":"Sporn","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41416-018-0264-x","article-title":"The colorectal cancer epidemic: Challenges and opportunities for primary, secondary and tertiary prevention","volume":"119","author":"Brenner","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"215158","DOI":"10.1155\/2010\/215158","article-title":"The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies","volume":"2010","author":"Sobolewski","year":"2010","journal-title":"Int. J. Cell Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/jnci\/djj206","article-title":"Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors","volume":"98","author":"Maier","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"97","DOI":"10.31557\/APJCP.2021.22.S1.97","article-title":"Antitumour Activities of Selected Pure Compounds Identified from the Serum of Crocodylus porosus, Malayopython reticulatus, Varanus salvator and Cuora kamaroma amboinensis","volume":"22","author":"Jeyamogan","year":"2021","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/JTO.0000000000000082","article-title":"A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer","volume":"9","author":"Gitlitz","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_77","first-page":"293","article-title":"Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis","volume":"60","author":"Reddy","year":"2000","journal-title":"Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.21037\/atm-20-4441","article-title":"The potential adjunctive benefit of adding metformin to standard treatment in inoperable cancer patients: A meta-analysis of randomized controlled trials","volume":"8","author":"Wu","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/S0301-472X(99)00087-9","article-title":"Cyclooxygenase-2 is essential for normal recovery from 5-fluorouracil-induced myelotoxicity in mice","volume":"27","author":"Lorenz","year":"1999","journal-title":"Exp. Hematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1359\/jbmr.2002.17.5.774","article-title":"Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines","volume":"17","author":"Ono","year":"2002","journal-title":"J. Bone. Miner. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_83","first-page":"1222","article-title":"Inhibition of COX-2\/PGE2 cascade ameliorates cisplatin-induced mesangial cell apoptosis","volume":"9","author":"Yu","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10549-008-0135-x","article-title":"Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow","volume":"117","author":"Lucci","year":"2009","journal-title":"Breast Cancer Res. Treat."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/9\/482\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:15:24Z","timestamp":1760141724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/9\/482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":84,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["curroncol29090482"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29090482","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]}}}